Key Points
- Insider Karen Soares sold 19,275 CLOV shares at an average price of $4.66, generating approximately $89,822. She retains 1.57 million shares, and the transaction was conducted under a pre-arranged Rule 10b5-1 plan.
- Clover Health recently exceeded quarterly expectations, reporting $0.05 in earnings per share versus the $0.04 consensus and revenue of $743.17 million against estimates of $728.27 million.
- Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $4.75. Institutional investors own about 19.77% of the company, while several funds recently initiated or increased positions.
Clover Health Investments, Corp. (NASDAQ:CLOV - Get Free Report) insider Karen Soares sold 19,275 shares of the company's stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $4.66, for a total transaction of $89,821.50. Following the completion of the sale, the insider directly owned 1,573,423 shares of the company's stock, valued at approximately $7,332,151.18. This represents a 1.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Karen Soares also recently made the following trade(s):
- On Thursday, October 15th, Karen Soares sold 14,673 shares of Clover Health Investments stock. The shares were sold at an average price of $4.68, for a total transaction of $68,669.64.
- On Tuesday, September 15th, Karen Soares sold 6,846 shares of Clover Health Investments stock. The shares were sold at an average price of $4.78, for a total transaction of $32,723.88.
Clover Health Investments Price Performance
NASDAQ CLOV opened at $4.80 on Wednesday. Clover Health Investments, Corp. has a 12 month low of $1.58 and a 12 month high of $5.59. The firm has a market capitalization of $2.55 billion, a PE ratio of -95.98 and a beta of 2.45. The company's 50 day simple moving average is $4.46 and its 200 day simple moving average is $4.05.
Clover Health Investments (NASDAQ:CLOV - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.01. The firm had revenue of $743.17 million during the quarter, compared to the consensus estimate of $728.27 million. Clover Health Investments had a negative return on equity of 4.20% and a negative net margin of 0.74%. Sell-side analysts anticipate that Clover Health Investments, Corp. will post 0.06 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
CLOV has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft began coverage on Clover Health Investments in a research note on Thursday, September 10th. They issued a "buy" rating and a $6.00 price objective on the stock. UBS Group upped their price objective on Clover Health Investments from $4.75 to $5.00 and gave the company a "neutral" rating in a report on Thursday, August 6th. Canaccord Genuity Group raised their target price on Clover Health Investments from $4.20 to $5.50 and gave the company a "buy" rating in a research note on Tuesday, July 21st. Zacks Research raised Clover Health Investments to a "hold" rating in a research note on Monday, September 14th. Finally, Wall Street Zen lowered Clover Health Investments from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 16th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $4.75.
Get Our Latest Stock Report on CLOV
Clover Health Investments News Roundup
Here are the key news stories impacting Clover Health Investments this week:
- Positive Sentiment: Clover Health earned top distinctions in U.S. News & World Report’s 2027 Medicare Advantage ratings across New Jersey, Georgia, and South Carolina. The recognition may support member growth, plan appeal, and the company’s competitive positioning in key markets. Clover Health Medicare Advantage ratings announcement
- Positive Sentiment: Institutional ownership activity was broadly constructive. Bank of New York Mellon, Tidal Investments, and Winton Group opened new positions, while California State Teachers Retirement System and AXQ Capital increased their holdings. Hedge funds and other institutions own approximately 19.77% of CLOV’s shares.
- Neutral Sentiment: Recent analyst views remain mixed. Deutsche Bank initiated coverage with a Buy rating and a $6.00 price target, while UBS raised its target to $5.00 but maintained a Neutral rating. The overall consensus remains Hold, with an average target of $4.75.
- Negative Sentiment: Several insiders reported sales: CEO Andrew Toy sold 62,176 shares, CEO Conrad Wai sold 23,627 shares, and Karen Soares sold a combined 33,948 shares. The transactions totaled roughly $469,000 based on the reported sale prices and modestly reduced their holdings.
- Negative Sentiment: The insider sales were executed under pre-arranged Rule 10b5-1 plans; the earlier transactions were specifically used to cover tax-withholding obligations related to equity vesting. This reduces their usefulness as a bearish signal, although repeated insider selling can still weigh on sentiment. Clover Health SEC insider filing
Institutional Investors Weigh In On Clover Health Investments
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp bought a new stake in shares of Clover Health Investments during the 2nd quarter worth $6,346,000. California State Teachers Retirement System grew its holdings in shares of Clover Health Investments by 24.1% in the 1st quarter. California State Teachers Retirement System now owns 497,006 shares of the company's stock worth $875,000 after acquiring an additional 96,458 shares during the last quarter. Tidal Investments LLC acquired a new position in shares of Clover Health Investments in the 2nd quarter worth $2,156,000. Turtle Creek Wealth Advisors LLC grew its holdings in shares of Clover Health Investments by 29.4% in the 1st quarter. Turtle Creek Wealth Advisors LLC now owns 220,000 shares of the company's stock worth $387,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new position in shares of Clover Health Investments in the 1st quarter worth $309,000. Institutional investors and hedge funds own 19.77% of the company's stock.
Clover Health Investments Company Profile
(
Get Free Report)
Clover Health Investments, Corp. is a health insurance technology company focused on providing Medicare Advantage plans to eligible seniors in the United States. Its plans combine hospital, medical and prescription drug coverage with additional benefits that may vary by plan and location.
The company uses its Clover Assistant technology platform to provide physicians with data-driven insights intended to support clinical decision-making and care coordination. The platform aggregates member health information and helps participating providers identify care opportunities, manage chronic conditions and engage with patients.
Clover Health was founded in 2012 and became a publicly traded company in 2021 through a merger with a special purpose acquisition company.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
